In this video, Juan Carlos Cardet, MD, of the University of South Florida (USF) Health Morsani College of Medicine in Tampa, ...

Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...

The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...

AstraZeneca’s Fasenra (benralizumab) injected drug cuts the size of nasal polyps and nasal blockage in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company announced top ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...

There are currently five biologics approved to treat asthma, according to the American Academy of Allergy, Asthma, and Immunology: omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab.

The European Commission has approved the Committee for Medicinal Products for Human Use (CHMP) recommendation to change the terms of marketing authorization for Fasenra (benralizumab). It can now ...

Patients with asthma who switched biologics multiple times were younger, more likely to identify as Black, and had more ...

The Centers for Disease Control and Prevention typically coordinates between 17 and 36 investigations of foodborne illnesses involving multiple states each week. A report is posted weekly, but ...

The move comes just before a Biden administration deadline for Israel to deliver more aid to the enclave or risk a cutoff of military supplies. By Hiba Yazbek A day after the prime minister of ...

Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...

Antisemitic assaults on visiting Israeli soccer fans, and incendiary chants and attacks by some Israelis: Here’s what we know so far about the violence in Amsterdam last week. By Jim ...